Cancer, COVID
Conditions
Brief summary
The COVIDHELP study will prospectively evaluate the yet unknown clinical course of the COVID-19 infection in cancer patients and document the impact of potential infrastructural limitations on cancer care of COVID-19 positive patients. All patients consenting will provide peripheral blood samples for prospective biobanking with the aim of investigating immune response and immunity against COVID-19.
Detailed description
Based on patients, who are treated in the University Cancer Center Hamburg (UCCH) and its contracted partner network, which comprises all cancer treating departments at the University Medical Center of Hamburg-Eppendorf (UKE), as well as 19 office-based oncologists and 20 surrounding hospitals, recruitment for the study will be done as follows: (i) as a cancer patient during regular aftercare appointments who reports a current or past COVID-19 infection. (ii) as an acute COVID-19 patient who reports a prevalent cancer diagnosis Data will be collected as available from routine clinical care and includes demographic and biometric data, medical history, baseline data at inclusion as well as inpatient and intensive care unit admissions. Upon consent, patients will provide peripheral blood samples at time of inclusion and after 6 month. Recruitment is limited to a one-year period (April 2020 - April 2021).
Interventions
OTHERNo Intervention
No Intervention
Sponsors
University Hopsital Schleswig Holstein Campus Lübeck
University Hospital Schleswig-Holstein
Universitätsklinikum Hamburg-Eppendorf
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key inclusion criteria: * Known diagnosis of cancer * Known diagnosis of CoVID-19 infection * Age ≥ 18 years * Signed informed consent Key
Exclusion criteria
• refusal of participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-specific mortality rate | 2 years | COVID-19 associated mortality rate |
| Need of mechanical ventilation | 2 years | Measured in percentage |
| Duration of mechanical ventilation | 2 years | Measured in days from the date of intubation to the stop date of mechanical ventilation |
| Rate of hospitalization | 2 years | Measured in percentage |
| Duration of hospitalization | 2 years | Measured in days from date of admission to definitive discharge |
| Rate of admission to intensive care unit | 2 years | Measured in percentage |
| Length of stay in intensive care unit | 2 years | Measured in days from date of admission to intensive care unit to the date of discharge |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cellular and humoral immune response to COVID-19 infection | 6 month | Analysis of blood samples at time of diagnosis and after 6 month |
| Rate of patients, whose oncologic treatment had to be modified due to COVID-19 | 2 years | Measured in percentage. Modification is defined as cancellation, postponement or dose-adjustment of treatment. |
Countries
Germany
Contacts
Primary ContactKatja Weisel, MD
Backup ContactNiklas Boerschel, MD
Outcome results
None listed